5-Amino-1MQ vs Semaglutide
Updated 7 sources
Key differences
- 1Semaglutide 2.4 mg weekly produced 14.9% mean weight loss against 2.4% on placebo at 68 weeks in STEP 1 (1,961 adults). 5-Amino-1MQ has no human trial.
- 2In obese mice, 5-Amino-1MQ gave about 5.1% weight loss over 11 days against a 1.4% gain in controls, with no change in food intake.
- 3Semaglutide works by cutting appetite. 5-Amino-1MQ targets cellular energy metabolism, which is why people stack them instead of choosing.
- 4Semaglutide is an FDA-approved weekly injection. 5-Amino-1MQ is unapproved and mostly taken as daily oral capsules.
Side by side
Facts from each record, in the same words as their own pages.
| 5-Amino-1MQ | Semaglutide | |
|---|---|---|
| Category |
|
|
| Evidence |
|
|
| FDA status |
|
|
| WADA |
|
|
| Half-life |
|
|
| Routes |
|
|
| Reported doses |
|
|
| Most cited frequency |
|
|
| Vial sizes |
|
|
| Mixed vial keeps |
|
|
| Protocols on file |
|
|
Doses shown are what sources report, labelled by origin. Not medical advice.
Read each in full
Sources
7 sources, each checked by date. Record updated Oct 24, 2026. Numbers are restated in our own words and labelled by where they came from.
Clinical study3
- Wilding et al. 2021, Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1), NEJMNEJM · checked Oct 23, 2026
- Neelakantan et al. 2018, Selective and membrane-permeable small molecule inhibitors of NNMT reverse high fat diet-induced obesity in mice (Biochem Pharmacol)PubMed · checked Oct 23, 2026
- Awosemo et al. 2021, LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: pharmacokinetics and oral bioavailability (J Pharm Biomed Anal)PubMed · checked Oct 23, 2026
Regulatory4
- Ozempic Prescribing Information (rev. 01/2025)FDA · checked Oct 23, 2026
- Wegovy injection and tablets label (SPL v19, Jun 30 2026)DailyMed · checked Oct 24, 2026
- ClinicalTrials.gov search for 5-amino-1MQ, 5-amino-1-methylquinolinium and NNMT inhibitorClinicalTrials.gov · checked Oct 23, 2026
- FDA Warning Letter 718739, GenoGenix LLC, January 20, 2026FDA · checked Oct 23, 2026